Treatment of Panic Disorder with Comorbid Hypertension and Insomnia

Medication Options

• The American College of Physicians recommends switching to a serotonin-norepinephrine reuptake inhibitor (SNRI) such as venlafaxine after failing two SSRI trials, due to its greater response rates compared to other antidepressants in patients whose initial SSRI therapy failed 1, 2
• Venlafaxine has demonstrated superior efficacy for treating anxiety compared to fluoxetine in clinical trials, with a moderate to high strength of evidence 1, 2

Considerations for Hypertension

• The American Heart Association suggests that when treating patients with cardiovascular disease, SSRIs are generally preferred over SNRIs due to potential blood pressure effects of SNRIs at high doses, with a high strength of evidence 3
• If using venlafaxine, it is recommended to start at a low dose and monitor blood pressure regularly, as SNRIs can cause hypertension at higher doses, with a moderate strength of evidence 3

Addressing Insomnia

• The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment for insomnia management, with a high strength of evidence 3
• Mirtazapine can be considered for its benefits in addressing both depression/anxiety and sleep through sedating properties, with a moderate strength of evidence 3

Treatment Algorithm

• The treatment algorithm recommends starting venlafaxine at a low dose (37.5mg daily) and gradually titrating up while monitoring blood pressure, with a moderate strength of evidence 1, 3
• If hypertension worsens, switching to mirtazapine (15-30mg at bedtime) can address both anxiety and insomnia without worsening hypertension, with a moderate strength of evidence 3

Psychotherapy Component

• The American Academy of Child and Adolescent Psychiatry recommends combining medication with cognitive behavioral therapy (CBT) specifically for panic disorder, as this combination approach has shown superior outcomes compared to either treatment alone, with a high strength of evidence 4, 5

Medication Administration and Monitoring

• It is recommended to start with subtherapeutic doses as a "test dose" since initial adverse effects of antidepressants can include increased anxiety or agitation, with a moderate strength of evidence 4, 6
• Monitoring for blood pressure changes, especially with SNRIs, serotonin syndrome, sleep quality, and suicidal ideation is crucial, with a high strength of evidence 3, 4

Expected Outcomes

• Approximately 75% of patients will respond to a medication switch after failing initial SSRI therapy, with a moderate strength of evidence 1
• Combined medication and CBT offers the best chance of remission and long-term improvement, with a high strength of evidence 4, 5